[Anti-RANKL monoclonal antibody Denosumab (AMG162)].

Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) which blocks its binding to RANK, inhibiting the development and activity of osteoclasts, followed by suppression of bone resorption. Denosumb given subcutaneously twice yearly for 3 years was associated with a reduction in the risk of vertebral, nonvertebral and hip fractures but not with serious adverse events in women with osteoporosis. New horizon would be brought about by Denosumab, new molecular targeting pharmaceutics in the treatment of osteoporosis as well as rheumatoid arthritis and metastatic bone diseases.